MedTrace Logo

Relationship Between Anogenital Distance, Serum AMH, and mTESE in Klinefelter Syndrome

NCT06396117 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 56

Last updated 2024-05-02

No results posted yet for this study

Summary

Azoospermia, the absence of sperm in the ejaculate, affects approximately 1% of males and 15% of infertile men. Non-obstructive azoospermia (NOA) accounts for 60% of azoospermic patients, who rely solely on testicular sperm extraction (TESE) surgery for sperm harvesting. While conventional TESE (cTESE) and microdissection TESE (mTESE) are preferred methods, the lack of predictive biomarkers for successful sperm retrieval (SR) renders treatment unnecessary for many NOA males. However, research suggests that anti-Mullerian hormone (AMH) and anogenital distance (AGD) may serve as predictors of positive SR at mTESE in NOA males. AGD, a marker of fetal androgen disruption and adult outcomes, may also assess male reproductive potential by predicting normal genital growth and sperm creation. A cross-sectional study found a positive correlation between AGD and total sperm count, concentration, and motility in infertile men aged 25-38, providing valuable prognostic insights for azoospermic men.

Conditions

  • Azoospermia Anogenital Distance AMH

Interventions

OTHER

mTESE (microscopic testicular sperm extraction)

Microdissection Testicular Sperm Extraction (mTESE) is a surgical procedure used to retrieve sperm from the testicles of men with non-obstructive azoospermia (NOA). It involves: 1. Testicular biopsy: Removing a small sample of testicular tissue. 2. Microscopic examination: Examining the tissue under a microscope to identify areas with sperm production. 3. Sperm extraction: Dissecting out individual sperm cells from the testicular tissue. This technique allows for: * More accurate identification of sperm-containing areas * Lower risk of damage to surrounding testicular tissue * Potential for higher sperm retrieval rates compared to conventional method

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2024-01-01
Completion
2024-02-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06396117 on ClinicalTrials.gov